

From: Liverpool-ECMC
Sent: 15 July 2019 10:34
To: Liverpool-ECMC
Subject: Liverpool ECMC Newsletter July 2019

LIVERPOOL ECMC NEWSLETTER JULY 2019

NEW ECMC CLINIC COMING AUGUST 2019

A new weekly ECMC clinic will be running on Monday afternoons at CCC for ECMC trials.

Patients who are interested in Phase I and non-randomised Phase II trials can be referred to this clinic through the new **ECMC e-mail address**.



NEW TRIALS OPENING

- **NICO** – Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in oral cavity cancer – *squamous cell carcinoma of the oral cavity*.

[Find out more...](#)

OPEN TRIALS

Please contact **Jennie Derham** for potential referral to these trials.

- Telephone: 0151 556 5443
- Mobile: 07554 416 293



ADVANCED SOLID TUMOURS

- **ACIT-1** – A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients – *All advanced solid tumours*.
- **BeiGene BGB-290-106** – A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib following Single Oral Dose Administration in Patients with Advanced and/or Metastatic Solid Tumors – *Advanced or Metastatic Solid Tumours*.
- **REPLIMUNE RP1** – An Open-Label, Multicenter, Phase 1/2 Study of RPI as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors – *Soft tissue sarcoma, stage III-IV melanoma, triple negative breast cancer, non-small cell lung cancer and non-melanoma skin cancer*.

BREAST

- **plasmaMATCH** – A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening – *Advanced breast cancer*.

HEAD & NECK

- **Cambridge Brain Mets Trial 1** – A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy – *Brain metastases from lung or breast primary*.
- **WISTERIA** - A Phase I trial of WEE1 inhibition with Chemotherapy and Radiotherapy as adjuvant treatment, and a Window of Opportunity trial with Cisplatin in Patients with Head and Neck Cancer – *Oral, laryngeal or hypopharyngeal squamous cell carcinoma*.

HPB / UPPER GI

- **BLU 554** – A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma – *Hepatocellular carcinoma and cholangiocarcinoma*.
- **OUTREACH** – A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH) – Advanced liver cancer.
- **POLARIS** - Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma - *Hepatocellular Carcinoma*

NON-CTIMPS

- **HYST** – Hypersensitivity Study: A Mechanistic Investigation into Drug and Chemical Induced Hypersensitivity Reactions
- **PRIMM** – Predicting Response to Immunotherapy for Melanoma with gut Microbiome and metabolomics (the PRIMM study)
- **PROACT** – Patient Reported Opinions About Clinical Tolerability
- **SMP-2** – The Cancer Research UK Stratified Medicine Programme: Pilot Study

Find out more...

EVENTS & JOB OPPORTUNITIES

EVENTS

- **[New directions in Immuno-Oncology \(SEPTEMBER 2019\)](#)**
- **[Successful nursing in a Phase I environment \(OCTOBER 2019\)](#)**
- **<https://www.ecmcnetwork.org.uk/events>**

CONTACT US

If you require any information which isn't on the website please contact the Liverpool ECMC Team via **e-mail**.

Copyright © 2019 Liverpool ECMC, All rights reserved.

Our mailing address is:

livecmc@liv.ac.uk